Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Thrombotic Disorders and antithrombotic therapy
Animal and experimental models
Antiphospholipid antibodies
Cancer and thrombosis
Cerebrovascular disease
Clinical trials: antiplatelet agents
Clinical trials: direct antithrombin agents
Clinical trials: fibrinolytic therapy
Clinical trials: heparins/LMWH
Clinical trials: oral anticoagulants
Diabetes and metabolic disorders
DVT and pulmonary embolism
Familial thrombosis
Gene therapy
Genetic determinants and epidemiology
Homocysteine
Hormone, pregnancy
Hypercoagulability
Inflammation, infection and immunity
Ischaemic heart disease
New antithrombotic agents and approaches
New intravascular devices
Other thrombotic disorders and antithrombotic therapy
Polymorphism and arterial disease
TTP and HUS
A comparison of argatroban and lepirudin outcomes
Smythe M.
Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
Lassen M., Bauer K. A., Eriksson B. I., Turpie A. G. G.
Anticoagulant effects of marinorm in coronary artery disease patients with hyperlipidemia
Karayeva N.
Antithrombotic action of perindopril in experimental venous thrombosis in young rats
Buczko W., Stankiewicz L., Buczko P., Chabielska E.
Anti-thrombotic effect of combination of low molecular weight heparin with low doses of unfractionated heparin in experimental venous thrombosis
Carelli G., Maffei F. H. A., Mattar L., Ferrari I. C., Carvalho L. C.
Antithrombotic effects of selective P2Y1 and P2Y12 antagonists in anesthetized rats
Vemulapalli S., Kurowski S., Fantuzzi J., Sabin C., Clasby M., Chackalamannil S., Hunter J., Graziano M., Chintala M.
Biological and pharmacokinetic activity of the new recombinant thrombolytic and anthithrombotic agent RGD SAK-K2-HIR
Szemraj J., Chabielska E., Rozponczyk E., Walkowiak B., Kawecka I., Janizewska G., Buczko W., Bartowiak J.
Consistency of efficacy of extended thromboprophylaxis with fondaparinux (Arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study
Eriksson B. I., Lassen M. R.
Cost-effectiveness of fondaparinux (Arixtra®) compared with enoxaparin as prophylaxis against venous thromboembolism following major orthopedic surgery
Annemans L., De Groot K.
DX-9065a, a direct factor Xa inhibitor prevents both arterial and venous thrombosis in rats via blocking prothrombinase complex activity – comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor
Fukuda T., Honda Y., Matsumoto C., Ishihara H., Sugiyama N.
Effect of extra virgin olive oil on experimental thrombosis and primary haemostasis in rats
Brzosko S., De Curtis A., Murzilli S., Cerletti C., Donati M. B., De Gaetano G., Iacoviello L.
Efficacy of fondaparinux (Arixtra) in extended thromboprophylaxis in hip fracture surgery is irrespective of patient and surgical characteristics: subgroup analyses of the Penthifra-Plus study
Lassen M. R., Eriksson B. I.
Fibrinopeptide-A generation inhibition by anti-Xa drugs and its correlation with activated clotting time
Demir M., Iqbal O., Schultz C., Ma Q., Hoppensteadt D., Fareed J.
Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis)
Cohen A. T., Gallus A. S., Lassen M. R., Tomkowski W., Turpie A. G. G., Davidson B. L., Cariou R. G., Lensing A. W. A., Egberts J. F. M.
Heparinase I digestion of tinzaparin: a novel approach to neutralize the anti-coagulant and potential hemorrhagic effects of low molecular weight heparin
Schultz C., Iqbal O., Hoppensteadt D., Ma Q., Tobu M., Florian-Kujawski M., Fareed D.
Influence of argatroban alone and combined with oral anticoagulants on the assessment of coagulation factors
Walenga J. M., Drenth A., Mayuga M., Hoppensteadt D., Harder S., Watanabe H., Osakabe M., Breddin H. K.
Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism (VTE) following major orthopedic surgery
Eriksson B., Bauer K. A., Lassen M. R., Turpie A. G. G.
International collaborative study on analyzing methods for determination of direct thrombin inhibitors
Gray E., Harenberg J.
Intimatan ameliorates the activation of human platelets by heparin/heparin antibody from patients with heparin-induced thrombocytopenia
Walenga J. M., Prechel M. M., Jeske W. P., Cardin A. D., Van Gorp C., Bakhos M.
Lack dose-response with Fondaparinux and Idraparinux is due to endogenous antithrombin saturation
Hoppensteadt D., Walenga J., Jeske W., Fareed J.
Local blockade of vWF binding epitopes on damaged vessel wall exposed collagen with Saratin inhibits thrombotic risk at different hemodynamic conditions
Vilahur G., Casani L., Duran X., Sánchez-Gómez S., Badimon L.
Maintenance doses of lepirudin (Refludan), as adjusted by a chromogenic substrate assay (CSA), highly suggest that recommended therapeutical doses should be safely reduced
Piquet P., Doubine S., Parquin F.
Measurement of synthetic pentasaccharide fondaparinux (arixtra) anti-Xa activity
Depasse F., Gerotziafas G. T., Van Dreden P., Fontaine S., Samama M. M.
No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
Bauer K. A., Lassen M. R., Turpie A. G. G., Eriksson B. I.
Oral antithrombin agents comprise the regulatory functions of thrombin
Fareed D., Bacher P., Hoppensteadt D., Walenga J. M., Ma Q., Bick R.
Orally active integrin antagonists perturb aIIbb3 integrin conformation
Hantgan R. R., Mousa S. A., Feuerstein G. Z.
Persistence of the risk of venous thromboembolism (VTE) for at least four weeks after hip fracture surgery: evidence from the fondaparinux hip fracture surgery database
Eriksson B. I., Lassen M. R.
Pharmacodynamic profile of Intimatan as an antithrombotic agent for venous thrombosis
Walenga J. M., Ma Q., Schultz C., Jeske W. P., Cardin A. D., Van Gorp C., Bakhos M.
Pharmacodynamics and pharmacokinetics of anti-Xa potency adjusted heparin derived oligosaccharides in nonhuman primates: implications in dosage optimization
Ma Q., Schultz C., Tobu M., Hoppensteadt D., Cornelli U., Fareed J.
Phospholipid-dependent impairment of the inhibitory properties of hirudin: the cause of false-positive assays for lupus anticoagulants (LAs)
Howard T. E., Channell C., Waddy S., Benson E., Duncan A.
Relevance of venographic distal thrombus assessment in venous thromboembolism (VTE) prophylaxis studies: lessons from the fondaparinux (Arixtra®) database in major orthopedic surgery
Turpie A. G. G., Bauer K. A., Eriksson B. I., Lassen M. R.
Reteplase and direct thrombin inhibitors: concurrent use for acute thrombotic events in patients with heparin-induced thrombocytopenia
Sheikh M., Begelman S. M.
Reviparin normalizes tissue factor pathway activation in patients with lower limb immobilization and is not associated with heparin antibody production
Kaiser P., Prechel M., Hoppensteadt D., Bacher P., Misselwitz F., Lassen M. R., Walenga J. M.
Serine proteases–mediated serotonin release and its inhibition by argatroban and other direct thrombin inhibitors: Implications in the control of thrombogenesis
Ahmad S., Fenton J. W., Osakabe M., Iqbal O., Hoppensteadt D. A., Messmore H. L., Fareed J.
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747, a novel P2Y12 receptor antagonist
Jakubowski J., Ogawa T., Sugidachi A., Hasegawa M., Tsutsumi S., Yoneda K., Iwamura R., Kimura T., Asai F.
Synthetic inhibitors of coagulation factor Xa suppress thrombin generation without affection on initial thrombin forming time
Tarumi T., Ieko M., Takeda M., Naito S., Arai J., Nakabayashi T., Notoya A., Koike T.
The effect of orally administered heparins on a rat carotid arterial model of thrombosis
Hiebert L. M., Pinel C., Wice S. M.
The Gas6 receptors Axl, Sky, and Mer function to enhance human platelet degranulation and aggregation
Perrin L. A., Gould W. R., Baxi S. M., Peterson J. T., Leadley R.
The role of tissue factor on the inhibition of prothrombin activation and thrombin generation by the synthetic pentasaccharide (fondaparinux)
Gerotziafas G., Depasse F., Chakroun T., Van Dreden P., Elalamy I., Samama M. M.
The role of tissue factor on the inhibition of prothrombin activation and thrombin generation by the synthetic pentasaccharide (fondaparinux)
Gerotzuafas G. T., Depasse F., Chakroun T., Van Dreden P., Elalamy I., Samama M. M.
Thrombolytic effect of AT1 receptor antagonists – losartan and its metabolite EXP 3174 in rat
Chabielska E., Nazarko J., Rozmyslowicz W., Mogielnicki A., Buczko W.
Timing of initial administration of prophylaxis against deep vein thrombosis in patients following hip or knee surgery
Hull R. D., Burke N., Mah A. F., Pineo G. F.
Two sensitive chromogenic assays of fondaparinux sodium (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in plasma
Paolucci F., Van Aarle F. G. B., Capdevila A., Clavies M. C., Donat F., Frasa W. L. H., Frasa W. L. H., Hendriks-Linders Y. E. M., Nadal T., Necciari J., Perez Y., Van Den Heuvel M. W., Van Dinther T. G.
Use of aprotinin as an antidote in activated protein C related bleeding
Madlener K., Mueller J., Poetzsch B.
Variability in antifactor Xa assay procedures
Koerber J. M., Mattson J. C., Smythe M. A.